NCT04662281

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	Placebo	LX9211 matching-placebo, tablets will be administered orally.
DRUG	LX9211	LX9211 tablets will be administered orally.

Timeline

• Start date: 2020-12-10
• Primary completion: 2022-11-18
• Completion: 2022-12-28
• First posted: 2020-12-10
• Last updated: 2026-02-13
• Results posted: 2026-02-13

Locations

32 sites across 3 countries: United States, Czechia, Poland

Regulatory

• FDA-regulated drug study